Botulinum Toxin Treatment in Patients with Facial Synkinesis

  • R. Laskawi
  • W. Damenz
  • P. Roggenkämper
  • A. Baetz


Botulinum toxin therapy (BTT), originally applied to treat strabism (for review see [8]), is now established as a minimally invasive, successful therapy in a number of diseases. The treatment of mass movements (synkinesis) following paralysis of the facial nerve, which may have various etiologies, has recently been reported as another indication. First experiences with BTT, applied to several patients with such synkinesis, were published by Roggenkämper et al. [7]. This indication was also confirmed by case reports by other authors [2, 6]. According to Roggenkämper et al. [7] this treatment is effective for an average of 11 weeks after the first injection, according to patients’ personal assessment.


Facial Nerve Botulinum Toxin Mass Movement Facial Nerve Paralysis Botulinum Toxin Injection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Brudny J, Hammerschlag PE, Cohen NL, Ransohof J., (1988) Electromyographic rehabilitation of facial function and introduction of a facial paralysis grading scale for hypoglossal-facial nerve anastomosis. Laryngoscope 98: 405–410PubMedCrossRefGoogle Scholar
  2. 2.
    Dressler D, Schönle PW., (1990) Botulinum toxin to suppress hyperkinesias after hypoglossal-facial nerve anastomosis. Eur Arch Otorhinolaryngol 247: 391–392PubMedCrossRefGoogle Scholar
  3. 3.
    Fisch U., (1986) Extracranial surgery for facial hyperkinesis. In: May M., (ed) The facial nerve. Thieme, Stuttgart, chapter 27, pp 509–523Google Scholar
  4. 4.
    Fowler EP., (1939) Abnormal movements following injury to the facial nerve. J AMA 1003–1008Google Scholar
  5. 5.
    Lamy H., (1905) Note sur les contractions “synergiques paradoxales” observé ä suite de la paralysie faciale périphériques. Nouv Iconogr Salpetr 18: 424–425Google Scholar
  6. 6.
    Putterman AM., (1990) Botulinum toxin injections in the treat-ment of seventh nerve misdirection. Am J Opthalmol 205–206Google Scholar
  7. 7.
    Roggenkämper P, Laskawi R, Damenz W, Schröder M, Nüßgens Z., (1990) Botulinus-Toxin-Behandlung bei Synkinesien nach Fazialisparese. HNO 38: 295–297Google Scholar
  8. 8.
    Scott AB., (1989) Botulinum-toxin therapy of eye muscle dis-orders. Safety and effectiveness (ophthalmic procedures assessment, American Academy of Ophthalmology ). Ophthalmology, instrument and book issueGoogle Scholar
  9. 9.
    Shimono T, Hattori N, Yamamoto T, Takimoto I., (1989) EMG- biofeedback therapy for reduction of synkinesis. Facial N Res Jpn 9: 189–192Google Scholar
  10. 10.
    Stennert E, Limberg CH, Frentrup KL (1977) Parese und Defektheilungsinder — ein leicht anwendbares Schema zur Objektivierung und Bewertung von Therapieerfolgen bei Fazialisparesen. HNO 25: 238–245Google Scholar
  11. 11.
    Stennert E., (1981) Komplikationen und Rückstände nach operativen Eingriffen am Nervus facialis. In: Miehlke A, Stennert E, Arold R., Motorische Nerven. Arch Ohren Nasen Kehlkopfheilkd, 231, (1 TA)Google Scholar
  12. 12.
    Stennert E., (1982) Das autoparalytische Syndrom — ein Leit-symptom der postparetischen Fazialisfunktion. Arch Otorhinolaryngol 236: 97–114PubMedCrossRefGoogle Scholar
  13. 13.
    Sunderland S., (1977) Mass movement after facial nerve injury. In: Fisch M., (ed) Facial nerve surgery. Kugler, Amstelveen, pp 285–289Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • R. Laskawi
    • 1
  • W. Damenz
    • 1
  • P. Roggenkämper
    • 2
  • A. Baetz
    • 1
  1. 1.ENT-DepartmentUniversity of GöttingenGöttingenGermany
  2. 2.Department of OphtalmologyUniversity of BonnGermany

Personalised recommendations